Category 2 peptides: what the access limits mean for patients

The FDA’s Category 2 designation is not a permanent ban — but right now it means certain peptides are not legally available through licensed compounding pharmacies.

TL;DR

• Category 2 peptides — including BPC-157, TB-500, and MOTS-c — cannot currently be compounded by 503A pharmacies under FDA rules.
• Limited legal access pushes some patients toward unregulated gray-market sources, which carry real risks.
• A February 2026 HHS announcement proposed reclassification, but formal FDA action had not been published as of June 2026.

What it is

The FDA reviews bulk drug substances — the raw ingredients compounding pharmacies use. It places each one into a category. Category 1 substances have enough evidence to be permitted in compounding. Category 2 means the FDA found insufficient evidence to support compounding under Section 503A. That is the law governing most retail compounding pharmacies. As a result, 503A pharmacies cannot legally compound Category 2 substances (FDA, 2024).

Peptides currently in Category 2 include BPC-157 (body protection compound), TB-500 (thymosin beta-4 synthetic), and MOTS-c (mitochondrial open reading frame of the twelve S rRNA-c). Each was nominated for compounding use, reviewed, and placed in Category 2 due to gaps in clinical evidence.

How it works

Imagine a licensed kitchen that can only use ingredients from an approved supplier list. If an ingredient is not on the list, the kitchen cannot legally use it. Demand doesn’t change that. Promising early research doesn’t either. Category 2 is that “not on the list” status.

The ingredient may still be studied in research settings. It may eventually be reclassified. But today, a licensed 503A pharmacy cannot fill a prescription for it.

Who asks about it

People come here after reading about BPC-157, TB-500, or MOTS-c — in research articles, from a physician, or in health communities. They discover a licensed pharmacy cannot fill the prescription. They want to know why. And they want to know what their legal options actually are.

What the research says

The evidence base for Category 2 peptides is mostly preclinical. That means studies in animals or cell cultures, not human clinical trials. The FDA’s category determination reflects that gap. Federal Register notices document the agency’s review of available literature and its reasoning (Federal Register, 2021; FDA, 2024). In February 2026, HHS proposed returning several Category 2 peptides to Category 1. As of this writing, the formal FDA Federal Register notice had not been published.

What to know before considering it

Patients who cannot access Category 2 peptides through licensed channels sometimes turn to vendors selling products labeled “research use only.” These are not made under the sterile compounding standards required of licensed pharmacies. Potency, purity, and sterility are unverified. Any peptide access requires a licensed clinician. If a peptide you want is in Category 2, your physician can advise on legal options and track regulatory changes as they happen.

The Halftime POV

At Halftime Health, we follow peptide regulatory status closely because it changes. Our patients deserve accurate information about what is and is not legally available. We do not prescribe Category 2 substances. We will update our protocols as the FDA Federal Register reflects any formal reclassification.

Related reading:

• Why certain peptides are still in Category 2
• The February 2026 HHS reclassification announcement
• 12 peptides removed from FDA restriction in 2026
• The three-category access model explained
• FDA reclassification April 2026 explained

FAQ

Q: What does FDA Category 2 mean for a peptide? A: Category 2 means the FDA has determined, after review, that there is insufficient evidence supporting the use of a substance in compounding under Section 503A. As a result, 503A compounding pharmacies cannot legally compound that substance.

Q: Are BPC-157, TB-500, and MOTS-c currently available from compounding pharmacies? A: As of June 17, 2026, these peptides remain in Category 2 and are not legally available from 503A compounding pharmacies in the United States. A February 2026 HHS announcement proposed reclassification, but FDA Federal Register notice formalizing any change had not been issued as of this date.

Q: What is the patient risk of seeking Category 2 peptides outside licensed pharmacies? A: Unlicensed online vendors may sell peptides labeled “research use only.” These products are not manufactured under the sterile compounding standards required of licensed pharmacies, and potency, purity, and sterility are unverified.

Q: What is the difference between Category 1 and Category 2? A: Category 1 bulk drug substances have sufficient evidence to support their use in compounding and are permitted. Category 2 substances are not currently permitted. A third category covers substances nominated but not yet reviewed.

Q: How should patients find out the current regulatory status of a specific peptide? A: The FDA maintains an updated list of 503A bulk drug substance categories at fda.gov. Your prescribing physician can also advise on what is legally accessible through licensed channels at any given time.

Disclaimer

As of June 17, 2026, several peptides discussed in this article — including BPC-157, TB-500, and MOTS-c — are classified by the FDA as Category 2, which means they are not currently available from 503A compounding pharmacies. A February 2026 HHS announcement proposed returning these peptides to Category 1 pending formal FDA Federal Register notice. This article is educational and is not medical advice. Halftime Health only prescribes through licensed clinicians in states where our partner physicians are credentialed.

Get updates

Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.

Sources

• U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A. FDA, 2024. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a
• U.S. Department of Health and Human Services. HHS Announcement on Peptide Reclassification. February 2026. [Federal Register reference pending formal publication.]
• Federal Register. Bulk Drug Substances That May Be Used in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. 2021. https://www.federalregister.gov